Stock Analysis·← Pickers

BWAY

BrainsWay Ltd.

BrainsWay Ltd. (BWAY) is currently in a range/mixed trend, above the 200-day MA but below the 50-day MA. RSI is at 50.1, with 2/3 trend checks passing.

Price
$14.89
2026-07-16
Trend score
2/3
Range / Mixed
RSI (14)
50.1
Neutral
Price above MA50Price above MA200MA50 above MA200
Change stock
Search another ticker to view its stock analysis page.
Chart View

BWAY with MA50 and MA200

17.1714.3111.468.605.7407/3110/2401/2204/1707/15
BWAY2025-07-312026-07-15
PriceMA50MA200
Technical Indicators

Key levels & signals

MA50
$15.16-1.77% vs price
MA200
$11.91+24.99% vs price
RSI (14)
50.1Neutral zone
MACD Signal
MixedMACD near signal line
Macro Support
Not identifiedNo repeated weekly support zone found
Support Quality
Volume data unavailable
Chart Summary
Trend summary for BWAY

BrainsWay Ltd. (BWAY) looks more range-bound than strongly trending, but there are still a few supportive signs on the chart. The latest available price is $14.89, and 2 of 3 core trend checks are currently passing. Price is trading below the 50-day moving average by 1.8% and above the 200-day moving average by 25.0%.

Momentum and stretch context

BWAY currently has an RSI reading of 50.1, which sits in a neutral range. That usually means momentum is not especially stretched in either direction, so traders may need to rely more on chart structure than on oscillator extremes alone.

What traders may watch next

This page is designed to help you quickly understand what the BWAY chart looks like before opening the full dashboard. The aim is not to tell you what to buy or sell, but to make it easier to judge whether the stock is trending cleanly, becoming stretched, or simply moving in a more awkward range.

Company profile

About BrainsWay Ltd.

BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets. Its primary offering is the Deep Transcranial Magnetic Stimulation (dTMS) platform technology, which provides treatment for various ailments including major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's clientele primarily comprises medical professionals, hospitals, and medical centers specializing in psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.

Sector
Healthcare
Industry
Medical - Devices
CEO
Hadar Levy
Employees
129
Market cap
$584.0M
Beta
0.15
52-week range
$5.68 – $17.35
Dividend
No
Exchange
NASDAQ
Country
IL
IPO date
17 Apr 2019
ISIN
US10501L1061
CUSIP
10501L106
Company profile data from Financial Modeling Prep. BWAY listed on NASDAQ.
Share dilution

BWAY shares outstanding over time

Tracking total shares outstanding is one way to spot dilution — a rising line means the company has issued more shares (stock-based compensation, secondary offerings, convertible debt), which spreads the same earnings and ownership across more shares. A falling line usually reflects buybacks.

Jun 2019Mar 2026
Shares outstanding (latest)
19.1M
Since Jun 2019
-6.6%
Trend
Fewer shares outstanding (buybacks)
Historical shares-outstanding data from Financial Modeling Prep. BWAY28 data points from Jun 2019 to Mar 2026.
Learn More

Learn the indicators behind this page

Explore More

More stock opportunities

FAQ

Common questions about BWAY

Is this page a buy or sell recommendation?

No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.

Why can a stock look bullish and overbought at the same time?

Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.

What should I do next after reading this page?

Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.